VYYRF - Voyageur Pharmaceuticals Ltd. Announces Health Canada Approval and Issuance of 5th Product License for MultiXThick Radiographic Barium Contrast
(TheNewswire)
Calgary, Alberta - TheNewswire- May 17, 2021 - Voyageur Pharmaceuticals Ltd. ( TSXV:VM) ( OTC:VYYRF ) (the "Company" or"Voyageur") is pleased to announce that it has receivedapproval from Health Canada (HC) for its fifth product, MultiXthick barium sulfatesuspension that contains 105% w/v barium sulfatesuspension for oral and rectal administration of the gastrointestinaltract.
Voyageur has built a full suite of barium radiographiccontrast media products for global sales and distribution. Thefollowing products have been licensed:
-
- SmoothX – For CTmarket
- HDX – For Flouroscopymarket
- LDX – For Fluoroscopymarket
- MultiXthin – For Flouroscopymarket
- MultiXthick- For Flouroscopymarket
Voyageur is focused on rolling out all its products ina timely manner. Smoothies for CT scans is one of the top volumeselling products in the USA and Canada. Voyageur is focused onlaunching SmoothX as our initial product to market. Voyageur iscurrently optimizing blending formulations and manufacturingprocedures to bring its newly-formulated products under GMP and HCguidelines. Voyageur will be working with a Canadian based imagingclinic to run clinical tests on patients to ensure our product meetsand exceeds the requirements for computed Tomography before we enterthe market. Voyageur plans to ensure that it is creating the highestquality products prior to phase one marketing, sales and distributionto Canadian, USA and international markets.
FDA applications are in progress and our objective isto acquire FDA device licensing to coincide with our product rollout.
Voyageur has begun business and product developmentwork with Dash Consulting to develop additional new improvedproducts for the CT, MRI and Fluoroscopy markets. Voyageur plans tocreate multiple new value added products to our product portfolio. Ourobjective is to create new products and product lines that exceedperformance of the products currently available on the market. Theseproducts are being developed to complement and enhance the latesttechnological advancements in radiographic technology. Voyageurbelieves these new products and their development will add significantvalue and allow our company to capture targeted marketsegments.
About Voyageur
Voyageur Pharmaceuticals Ltd. is a Canadian publiccompany listed on the TSX Venture Exchange under the trading symbolVM. Voyageur is focused on the development of barite and iodine,Active Pharmaceutical Ingredient (API) minerals. The near-term focusis developing barium and iodine radio-contrast pharmaceuticalproducts. Voyageur’s goal is to initially generate near termpositive cash flow from operations using third party GMPpharmaceutical manufacturers in Canada and internationally.Ultimately, Voyageur has plans to build all the requiredinfrastructure to become 100% self-sufficient with all manufacturing.Voyageur owns a 100% interest in three barium sulfate (barite)projects including two properties suitable in grade for the industrialbarite marketplace, with interests in a potentially high-grade iodine,lithium & bromine brine project located in Utah, USA.
Voyageur is moving forward with its business plan ofbecoming the only fully-integrated company in the radiographiccontrast medical field, by controlling all primary input costs underthe motto of: "From theEarth to the Bottle"
For Further Media Information or to set up aninterview, please contact:
Brent Willis
President & CEO
Ron Love
CFO
T 403.818.6086
E ronl@vpharma.ca
www.voyageurpharmaceuticals.ca
Forward Looking Information
This news release may contain certain forward-lookinginformation and statements, including, without limitation, statementspertaining to commercial launch of its products, including timing formarketing, sales and distribution of MultiXthin and the Company'sother barium radiographic contrast media products, the ability toobtain licenses in international jurisdictions, and to do soexpeditiously based on existing HC approvals, the Company's ability toobtain necessary approvals from HC for additional barium radiographiccontrast products, the closing of the second tranche of the Offeringand the timing thereof, and obtaining the necessary approvals of theTSX Venture Exchange. All statements included herein, other thanstatements of historical fact, are forward-looking information andsuch information involves various risks and uncertainties. There canbe no assurance that such information will prove to be accurate, andactual results and future events could differ materially from thoseanticipated in such information. A description of assumptions usedto develop such forward-looking information and a description of riskfactors that may cause actual results to differ materially fromforward-looking information can be found in the Company's disclosuredocuments on the SEDAR website at www.sedar.com. Voyageur does notundertake to update any forward-looking information except inaccordance with applicable securities laws.
Reader Advisory
Neither the TSXV nor its RegulationServices Provider (as that term is defined in the policies of theTSXV) accepts responsibility for the adequacy or accuracy of this newsrelease.
Copyright (c) 2021 TheNewswire - All rights reserved.